Neoadjuvant PD-1 inhibitor combined with FLOT versus SOX for locally advanced gastric cancer: a retrospective cohort study
Neoadjuvant PD-1 inhibitor plus SOX and plus FLOT yielded comparable response rates, survival outcomes, and safety profiles in patients with resectable LAGC/EGJ adenocarcinoma. PD-1+SOX was associated with less operative burden, and MPR remained independently associated with OS and RFS, supporting its value for risk stratification and treatment optimization.
Authors
- Z.Y. Li
- Lili Duan
- Liu Hong
- Xin Zhang
- Wanli Yang
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- 81th Hospital of PLA (CN)
- Xijing Hospital (CN)
- Guangzhou Medical University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3389/fimmu.2026.1782029
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00